NASDAQ:PLXP PLx Pharma Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding PLx Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.33 -0.30 (-8.26 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$3.33Now: $3.33▼$3.5050-Day Range$3.00MA: $3.58▼$4.2252-Week Range$1.80Now: $3.33▼$5.96Volume17,982 shsAverage Volume11,862 shsMarket Capitalization$30.49 millionP/E RatioN/ADividend YieldN/ABeta4.31 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. Its product pipeline also includes other oral non-steroidal anti-inflammatory drugs using the PLxGuard delivery system, such as PL1200 Ibuprofen 200 mg, a GI-safer ibuprofen product for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. The company was founded in 2002 and is headquartered in Houston, Texas.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for PLx Pharma. Previous Next 2.1 Community Rank Outperform VotesPLx Pharma has received 173 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPLx Pharma has received 243 “underperform” votes. (Add your “underperform” vote.)Community SentimentPLx Pharma has received 58.41% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about PLx Pharma and other stocks. Vote “Outperform” if you believe PLXP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PLXP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPLx Pharma does not currently pay a dividend.Dividend GrowthPLx Pharma does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PLx Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $32,908.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.51% of the stock of PLx Pharma is held by insiders.Percentage Held by InstitutionsOnly 22.00% of the stock of PLx Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PLx Pharma are expected to grow in the coming year, from ($1.49) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PLx Pharma is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PLx Pharma is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.15 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PLXP Previous Symbol CUSIPN/A CIK1497504 Webwww.plxpharma.com Phone973-409-6541Debt Debt-to-Equity RatioN/A Current Ratio2.66 Quick Ratio2.63Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$570,000.00 Price / Sales53.49 Cash FlowN/A Price / Cash FlowN/A Book Value($1.32) per share Price / Book-2.52Profitability EPS (Most Recent Fiscal Year)($4.74) Net Income$-20,500,000.00 Net Margins-4,906.25% Return on EquityN/A Return on Assets-81.02%Miscellaneous Employees12 Outstanding Shares9,156,000Market Cap$30.49 million Next Earnings Date11/13/2020 (Estimated) OptionableNot Optionable $3.33 -0.30 (-8.26 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PLXP News and Ratings via Email Sign-up to receive the latest news and ratings for PLXP and its competitors with MarketBeat's FREE daily newsletter. PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions How has PLx Pharma's stock been impacted by COVID-19 (Coronavirus)? PLx Pharma's stock was trading at $4.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PLXP shares have decreased by 30.8% and is now trading at $3.33. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of PLx Pharma? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PLx Pharma. When is PLx Pharma's next earnings date? PLx Pharma is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020. View our earnings forecast for PLx Pharma. How were PLx Pharma's earnings last quarter? PLx Pharma Inc (NASDAQ:PLXP) posted its earnings results on Friday, August, 14th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.03. The biotechnology company earned $0.03 million during the quarter. View PLx Pharma's earnings history. Are investors shorting PLx Pharma? PLx Pharma saw a increase in short interest in August. As of August 14th, there was short interest totaling 150,600 shares, an increase of 8.8% from the July 30th total of 138,400 shares. Based on an average daily volume of 14,200 shares, the days-to-cover ratio is presently 10.6 days. View PLx Pharma's Short Interest. Who are some of PLx Pharma's key competitors? Some companies that are related to PLx Pharma include Lumos Pharma (LUMO), Tonix Pharmaceuticals (TNXP), Strongbridge Biopharma (SBBP), Sierra Oncology (SRRA), Mallinckrodt (MNK), Leap Therapeutics (LPTX), OASMIA PHARMACE/ADR (OASM), Vaccinex (VCNX), Unum Therapeutics (UMRX), Capricor Therapeutics (CAPR), SUMMIT THERAPEU/S (SMMT), Zynerba Pharmaceuticals (ZYNE), Aclaris Therapeutics (ACRS), PhaseBio Pharmaceuticals (PHAS) and Antibe Therapeutics (ATBPF). View all competitors. What other stocks do shareholders of PLx Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other PLx Pharma investors own include Fulcrum Therapeutics (FULC), Energy Transfer LP Unit (ET), CymaBay Therapeutics (CBAY), VIVUS (VVUS), Paratek Pharmaceuticals (PRTK), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Abeona Therapeutics (ABEO) and ADMA Biologics (ADMA). Who are PLx Pharma's key executives? PLx Pharma's management team includes the following people: Mr. Michael J. Valentino, Exec. Chairman (Age 65)Ms. Natasha Giordano, CEO, Pres & Director (Age 59)Mr. Gary L. Mossman, Sr. Advisor (Age 78)Mr. Ronald R. Zimmerman, Founder & Sr. Advisor (Age 66)Ms. Rita M. O'Connor CPA, Chief Financial Officer (Age 51) When did PLx Pharma IPO? (PLXP) raised $68 million in an initial public offering (IPO) on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers. What is PLx Pharma's stock symbol? PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP." How do I buy shares of PLx Pharma? Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is PLx Pharma's stock price today? One share of PLXP stock can currently be purchased for approximately $3.33. How big of a company is PLx Pharma? PLx Pharma has a market capitalization of $30.49 million and generates $570,000.00 in revenue each year. The biotechnology company earns $-20,500,000.00 in net income (profit) each year or ($4.74) on an earnings per share basis. PLx Pharma employs 12 workers across the globe. What is PLx Pharma's official website? The official website for PLx Pharma is www.plxpharma.com. How can I contact PLx Pharma? PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company can be reached via phone at 973-409-6541 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
